Calidi Biotherapeutics, Inc.
CLDI
$1.74
$0.1811.54%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 14.60% | 33.61% | 24.21% | 8.59% | 27.53% |
| Total Depreciation and Amortization | 8.42% | 7.46% | 22.21% | 53.52% | 107.53% |
| Total Amortization of Deferred Charges | 128.26% | -88.26% | -89.58% | -128.67% | -107.27% |
| Total Other Non-Cash Items | 189.67% | -59.78% | -62.18% | -81.39% | -114.50% |
| Change in Net Operating Assets | -42.31% | -53.40% | 72.80% | 137.11% | -1,299.43% |
| Cash from Operations | 20.15% | 17.01% | 27.01% | 24.21% | -70.58% |
| Capital Expenditure | 48.98% | 96.03% | 97.26% | 88.02% | 78.09% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -44.44% | 1,266.67% |
| Cash from Investing | 27.18% | 94.80% | 96.65% | 92.38% | 84.72% |
| Total Debt Issued | -81.25% | -85.37% | 16.92% | -20.00% | -32.63% |
| Total Debt Repaid | 49.62% | -49.72% | 19.95% | -5,375.00% | -6,108.96% |
| Issuance of Common Stock | 393.72% | 32,846.00% | 8,038.79% | 3,189.32% | 2,306.06% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -100.00% | 275.67% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -71.28% | 26.82% | -23.46% | -64.78% | -66.81% |
| Cash from Financing | -0.37% | 14.84% | -5.78% | -68.89% | 41.97% |
| Foreign Exchange rate Adjustments | -237.50% | -372.73% | -116.67% | -328.57% | 140.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 451.06% | 4,104.46% | 384.59% | -181.97% | -167.84% |